MCU and pulmonary arterial hypertension: Furthermore, subsequent studies utilized anti-miR25 and anti-miR138 in pulmonary arterial hypertension (PAH) patients whose MCU expression is downregulated, and the final conclusion revealed the predictable overexpression of the MCU protein (40).